No connection

Search Results

AMN vs SPRY

AMN
AMN Healthcare Services, Inc.
BEARISH
Price
$20.49
Market Cap
$787.1M
Sector
Healthcare
AI Confidence
78%
SPRY
ARS Pharmaceuticals, Inc.
BEARISH
Price
$8.18
Market Cap
$812.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AMN
--
SPRY
--
Forward P/E
AMN
30.31
SPRY
-10.8
P/B Ratio
AMN
1.22
SPRY
7.11
P/S Ratio
AMN
0.29
SPRY
9.64
EV/EBITDA
AMN
7.87
SPRY
-4.13

Profitability

Gross Margin
AMN
29.37%
SPRY
60.13%
Operating Margin
AMN
1.33%
SPRY
-147.63%
Profit Margin
AMN
-10.14%
SPRY
-203.25%
ROE
AMN
-35.9%
SPRY
-92.33%
ROA
AMN
1.17%
SPRY
-33.05%

Growth

Revenue Growth
AMN
-7.7%
SPRY
-67.6%
Earnings Growth
AMN
321.3%
SPRY
--

Financial Health

Debt/Equity
AMN
1.37
SPRY
1.47
Current Ratio
AMN
1.05
SPRY
7.28
Quick Ratio
AMN
0.94
SPRY
6.93

Dividends

Dividend Yield
AMN
--
SPRY
--
Payout Ratio
AMN
0.0%
SPRY
0.0%

AI Verdict

AMN BEARISH

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.

Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss
SPRY BEARISH

SPRY exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. Despite a strong liquidity position (Current Ratio 7.28), the company is facing a catastrophic revenue collapse of -67.60% YoY and deep negative profit margins of -203.25%. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual data, which shows bearish insider selling and a 0/100 technical trend. The valuation remains speculative and disconnected from current operational performance.

Strengths
Very high current ratio (7.28) providing a short-term liquidity cushion
Strong quick ratio (6.93) indicating minimal reliance on inventory for liquidity
Positive gross margin (60.13%) suggesting a viable core product price point
Risks
Severe revenue contraction (-67.60% YoY)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Deeply negative profitability (Profit Margin -203.25%)

Compare Another Pair

AMN vs SPRY: Head-to-Head Comparison

This page compares AMN Healthcare Services, Inc. (AMN) and ARS Pharmaceuticals, Inc. (SPRY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile